Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.52 (market cap $46.22M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 105.6× KraneShares Hang Seng TECH Index ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KTEC | TVTX | |
|---|---|---|
Market Cap | $46.22M | $4.88B |
Volume | 22,698 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $18.36 | $67.52 |
52-Week Low | $11.41 | $26.79 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.61 with no recent price movement. The stock shows bearish technical signals with 15 sell indicators versus 2 buy signals. Fundamentally, the company reported $120.04M revenue in 2016 with a net loss of $697K, though cash flow improved to positive $2.77M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC faces mixed prospects with improving cash flow but inconsistent profitability. The bearish technical outlook and volatile earnings history suggest caution, though exposure to AI sector growth through ETF positioning offers potential upside. Key risks include competitive pressures and execution challenges in maintaining positive momentum.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
